171 related articles for article (PubMed ID: 38690288)
1. Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence.
van Hees EP; Morton LT; Remst DFG; Wouters AK; Van den Eynde A; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2024; 15():1368290. PubMed ID: 38690288
[TBL] [Abstract][Full Text] [Related]
2. T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion.
Morton LT; Wachsmann TLA; Meeuwsen MH; Wouters AK; Remst DFG; van Loenen MM; Falkenburg JHF; Heemskerk MHM
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288464
[TBL] [Abstract][Full Text] [Related]
3. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
Jahn L; Hombrink P; Hagedoorn RS; Kester MG; van der Steen DM; Rodriguez T; Pentcheva-Hoang T; de Ru AH; Schoonakker MP; Meeuwsen MH; Griffioen M; van Veelen PA; Falkenburg JH; Heemskerk MH
Blood; 2017 Mar; 129(10):1284-1295. PubMed ID: 28053195
[TBL] [Abstract][Full Text] [Related]
4. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
5. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
Imamura M; Shook D; Kamiya T; Shimasaki N; Chai SM; Coustan-Smith E; Imai C; Campana D
Blood; 2014 Aug; 124(7):1081-8. PubMed ID: 25006133
[TBL] [Abstract][Full Text] [Related]
6. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.
Denman CJ; Senyukov VV; Somanchi SS; Phatarpekar PV; Kopp LM; Johnson JL; Singh H; Hurton L; Maiti SN; Huls MH; Champlin RE; Cooper LJ; Lee DA
PLoS One; 2012; 7(1):e30264. PubMed ID: 22279576
[TBL] [Abstract][Full Text] [Related]
7. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
8. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
9. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
Liu E; Tong Y; Dotti G; Shaim H; Savoldo B; Mukherjee M; Orange J; Wan X; Lu X; Reynolds A; Gagea M; Banerjee P; Cai R; Bdaiwi MH; Basar R; Muftuoglu M; Li L; Marin D; Wierda W; Keating M; Champlin R; Shpall E; Rezvani K
Leukemia; 2018 Feb; 32(2):520-531. PubMed ID: 28725044
[TBL] [Abstract][Full Text] [Related]
10. Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
Uppendahl LD; Felices M; Bendzick L; Ryan C; Kodal B; Hinderlie P; Boylan KLM; Skubitz APN; Miller JS; Geller MA
Gynecol Oncol; 2019 Apr; 153(1):149-157. PubMed ID: 30658847
[TBL] [Abstract][Full Text] [Related]
11. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
12. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor.
Sahm C; Schönfeld K; Wels WS
Cancer Immunol Immunother; 2012 Sep; 61(9):1451-61. PubMed ID: 22310931
[TBL] [Abstract][Full Text] [Related]
13. Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer.
Parlar A; Sayitoglu EC; Ozkazanc D; Georgoudaki AM; Pamukcu C; Aras M; Josey BJ; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Duru AD; Sutlu T
Eur J Immunol; 2019 Aug; 49(8):1278-1290. PubMed ID: 31054264
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
15. NK cells specifically TCR-dressed to kill cancer cells.
Mensali N; Dillard P; Hebeisen M; Lorenz S; Theodossiou T; Myhre MR; Fåne A; Gaudernack G; Kvalheim G; Myklebust JH; Inderberg EM; Wälchli S
EBioMedicine; 2019 Feb; 40():106-117. PubMed ID: 30665853
[TBL] [Abstract][Full Text] [Related]
16. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
17. A TCR-based Chimeric Antigen Receptor.
Walseng E; Köksal H; Sektioglu IM; Fåne A; Skorstad G; Kvalheim G; Gaudernack G; Inderberg EM; Wälchli S
Sci Rep; 2017 Sep; 7(1):10713. PubMed ID: 28878363
[TBL] [Abstract][Full Text] [Related]
18. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
19. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
20. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.
Pouw N; Treffers-Westerlaken E; Kraan J; Wittink F; ten Hagen T; Verweij J; Debets R
Cancer Immunol Immunother; 2010 Jun; 59(6):921-31. PubMed ID: 20101507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]